Abstract: Compositions and methods are provided for treating a human metastatic cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: Recombinant mammalian helper enzymes for targeted transposition are described. The mammalian helper enzymes and corresponding donor DNAs can be used, e.g., for gene therapy.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for treating a human metastatic cancer. Specifically, the invention provides methods of treatment and methods for determining whether an individual suffering from a cancer is responding to an AXL decoy protein-based therapy, predicting responsiveness of an individual suffering from a cancer to treatment comprising an AXL decoy protein, and methods of selecting a therapy for an individual suffering from cancer.

Abstract: Gene therapy compositions and methods are provided that make use of novel transposases and/or chimeric transposases for targeted transposition.

Abstract: Gene therapy compositions and methods are provided that make use of novel transposases and/or chimeric transposases for targeted transposition.

Abstract: Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: Gene therapy compositions and methods are provided for targeting an ATP binding cassette subfamily A member 4 (ABCA4), or a functional fragment thereof, in a patient, thereby treating or mitigating Inherited Macular Degenerations including a Stargardt disease or other diseases that involve retinal degeneration.

Abstract: Gene therapy compositions and methods are provided for targeting a very low-density lipoprotein receptor gene (VLDLR) and a low-density lipoprotein receptor gene (LDLR) to lower total cholesterol and/or low-density lipoprotein cholesterol (LDL-C) in a patient, thereby treating or mitigating familial hypercholesterolemia.

Abstract: Gene therapy compositions and methods are provided that make use of transposases and/or chimeric transposases for targeted transposition, including engineered enzymes and nucleic acids encoding the same. The provided compositions and methods are suitable of treating, for example, an inherited or acquired disease in a patient, as well as treating and/or mitigating a variety of diseases.

Abstract: Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: Gene therapy compositions and methods are provided that make use of novel transposases and/or chimeric transposases for targeted transposition.

Abstract: Provided herein are methods and compositions relating to adenosine A2A receptor libraries having nucleic acids encoding for a scaffold comprising an adenosine A2A binding domain. adenosine A2A receptor libraries described herein encode for immunoglobulins including antibodies and single domain antibodies. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: Provided herein are methods and compositions relating to prostaglandin D2 receptor 2 (DP2 or CRTH2R) libraries having nucleic acids encoding for a scaffold comprising a CRTH2R binding domain. CRTH2R libraries described herein encode for immunoglobulins including antibodies and single domain antibodies. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: Compositions and methods are provided for treating a human metastatic cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.